T
Tim O B Eden
Researcher at Royal Hospital for Sick Children
Publications - 47
Citations - 2841
Tim O B Eden is an academic researcher from Royal Hospital for Sick Children. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 25, co-authored 46 publications receiving 2669 citations. Previous affiliations of Tim O B Eden include Children's of Alabama & St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.
TL;DR: The use of 6·5 mg/m2 dexamethasone throughout treatment for ALL led to a significant decrease in the risk of relapse for all risk‐groups of patients and, despite the increased toxicity, should now be regarded as part of standard therapy for childhood ALL.
Journal ArticleDOI
An infectious aetiology for childhood acute leukaemia: a review of the evidence
TL;DR: There are three current hypotheses concerning infectious mechanisms in the aetiology of childhood leukaemia: exposure in utero or around the time of birth, delayed exposure beyond the first year of life to common infections and unusual population mixing.
Journal ArticleDOI
Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia
Christine J. Harrison,Anthony V. Moorman,Zoë J. Broadfield,Kan L. Cheung,Rachel L. Harris,G. Reza Jalali,Hazel M. Robinson,Kerry E. Barber,Susan M. Richards,Chris Mitchell,Tim O B Eden,Ian Hann,Frank Hill,Sally E. Kinsey,Brenda Gibson,John S. Lilleyman,Ajay Vora,Anthony H. Goldstone,Ian M. Franklin,I. Jill Durrant,M Martineau +20 more
TL;DR: In this article, a study of children and adults with acute lymphoblastic leukaemia (ALL) is the largest series of patients with hypodiploidy (<46 chromosomes) yet reported.
Journal ArticleDOI
Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia
Anthony V. Moorman,Sue Richards,M Martineau,Kan Luk Cheung,Hazel M. Robinson,G. Reza Jalali,Zoë J. Broadfield,Rachel L. Harris,Kerry E. Taylor,Brenda Gibson,Ian Hann,Frank Hill,Sally E. Kinsey,Tim O B Eden,Chris Mitchell,Christine J. Harrison +15 more
TL;DR: It is confirmed that the outcome of children with HeH is heterogeneous and that specific trisomies can identify patients with the greatest and least risk of treatment failure.
Journal ArticleDOI
Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial
Ajay Vora,Chris Mitchell,Lynne Lennard,Tim O B Eden,Sally E. Kinsey,John S. Lilleyman,Susan M. Richards +6 more
TL;DR: Compared with 6-mercaptopurine, 6-thioguanine causes excess toxicity without an overall benefit and should remain the thiopurine of choice for continuing therapy of childhood lymphoblastic leukaemia.